Hospital

Although the pharmaceutical and biopharma industries must maintain reasonable profitability, they have a moral duty to society.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the eligibility requirements for patients included in the phase 2 trial results that led to the FDA approval of infigratinib.

Factors that may have contributed to the screening declines include site closures and temporary pausing of services.

The current study analyzed human tumor samples from 6 cancer types: liver, melanoma, colorectal, non-small lung, head and neck, and breast cancer.

Sacituzumab govitecan is approved for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 more prior systemic therapies.

Upadacitinib (RINVOQ; AbbVie), 15 mg or 30 mg and once daily, met the primary endpoint of clinical remission and all secondary endpoints at week 52 in a phase 3 ulcerative colitis study.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the findings of the phase 2 trial assessing infigratinib for treatment of previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze; Jazz Pharmaceuticals) provides a new alternative for a therapy in long-standing global shortage.

Study to evaluate the safety and efficacy of talazoparib, an oral PARP inhibitor, in combination with enzalutamide, an androgen receptor inhibitor.

Kirollos Hanna, PharmD, BCPS, BCOP, assistant professor of pharmacy at the Mayo Clinic College of Medicine and the oncology pharmacy manager at M Health Fairview - Maple Grove, discusses the potential impact of ACCC's Multiple Myeloma Dispensing Project on the field.

The COVID-19 pandemic has led to significant innovation, which presents a unique opportunity for pharmacists to advance pharmacy practice by serving as the integral drug monitoring experts of the health care team.

Researchers found an overall response rate of 29.8% in patients treated with 177Lu-PSMA-617, compared to a 1.7% partial response in the standard of care only arm.

The investigators found that population-based cancer registries showed a 10.2% decline in real-time electronic pathology reports in 2020 compared to 2019.

Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.

Umbralisib was granted accelerated approval by the FDA for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

Treatments to stimulate the release of eggs increase estrogen hormone production and can act on breast cells, which has created concern that this could turn the cells cancerous.

Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.

The use of high throughput technologies has revolutionized the understanding of the cancer genome.

Orelabrutinib is a highly selective Bruton's tyrosine kinase inhibitor designed to target B-cell lymphomas and autoimmune indications.

The DARE-19 clinical trial explores the use of SGLT2 inhibitors for patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease, and COVID-19.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Trilaciclib (Cosela) is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Initial data show that children presented with higher acuity in 2020 compared to the previous year.

The small-molecule inhibitors of the SOX 11 oncogene showed promise both as single agents and in combination with ibrutinib.

Azacitidine (Onureg) was approved by the FDA in September 2020 as a maintenance therapy for acute myeloid leukemia.

Panelists also recommended the use of bezlotoxumab as a co-intervention with standard of care antibiotics in patients with a recurrent C. diff infection within the past 6 months.

Ribociclib was found to prolong overall survival and improve post-progression outcomes in patients with HR-positive/HER2−negative advanced breast cancer, particularly among younger patients with a significant unmet need.

Results from the LOTIS-2 and LOTIS-3 trials show durable responses and a manageable toxicity profile among patients with both diffuse large B-cell lymphoma and mantle cell lymphoma treated with loncastuximab tesirine-lpyl (Zynlonta).